A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myleloid Leukemia
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    In order to participate in the study the following conditions must be met:
    1. Histologically or cytologically confirmed AML, as defined by World Health Organization (WHO) 2016 revised criteria (Döhner 2017), including secondary and therapy-relat

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. Known active CNS involvement (leukemic blasts in cerebrospinal fluid or imaging evidence of CNS disease).
    2. Diagnosis of acute promyelocytic leukemia.
    3. Any of the


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.